Updated: Sep 27
Our very own Dr. Rainer Lenhardt, Professor in the Department of Anesthesiology and Perioperative Medicine is the clinical trial lead (PI) in this ground breaking study.
The University of Louisville is conducting a clinical trial on a new treatment for critically ill COVID-19 patients meant to lessen some of the most severe and deadly respiratory effects.
The treatment, a new formulation of Aviptadil (RLF-100), produced by Pennsylvania-based NeuroRx and Relief Therapeutics Holding, SA, of Geneva, works by combating “cytokine storm,” an unchecked overreaction of the body’s immune response. These storms can cause severe lung inflammation and stiffening that make it difficult, if not impossible, for patients to breathe on their own.
“We want to mitigate these storms,” said the clinical trial lead, Dr. Rainer Lenhardt, associate professor of anesthesiology and critical care in the UofL School of Medicine. “We’re doing anything we can to improve outcomes.”
To read full article, please visit the link below: